Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5HIA

Human hypoxanthine-guanine phosphoribosyltransferase in complex with [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine

Summary for 5HIA
Entry DOI10.2210/pdb5hia/pdb
Related5HIG
DescriptorHypoxanthine-guanine phosphoribosyltransferase, [3-[(3~{R},4~{R})-3-(2-azanyl-6-oxidanylidene-1~{H}-purin-9-yl)-4-[(2~{S})-2-oxidanyl-2-phosphono-ethoxy]pyrrolidin-1-y l]-3-oxidanylidene-propyl]phosphonic acid, MAGNESIUM ION, ... (4 entities in total)
Functional Keywordspurine salvage, malaria, nuceloside phosphonate, enzyme, inhibitor, transferase
Biological sourceHomo sapiens (Human)
Cellular locationCytoplasm: P00492
Total number of polymer chains4
Total formula weight103688.34
Authors
Guddat, L.W.,Keough, D.T.,Rejman, D. (deposition date: 2016-01-11, release date: 2017-01-18, Last modification date: 2023-09-27)
Primary citationKeough, D.T.,Rejman, D.,Pohl, R.,Zbornikova, E.,Hockova, D.,Croll, T.,Edstein, M.D.,Birrell, G.W.,Chavchich, M.,Naesens, L.M.J.,Pierens, G.K.,Brereton, I.M.,Guddat, L.W.
Design of Plasmodium vivax Hypoxanthine-Guanine Phosphoribosyltransferase Inhibitors as Potential Antimalarial Therapeutics.
ACS Chem. Biol., 2017
Cited by
PubMed Abstract: Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are the foremost causative agents of malaria. Due to the development of resistance to current antimalarial medications, new drugs for this parasitic disease need to be discovered. The activity of hypoxanthine-guanine-[xanthine]-phosphoribosyltransferase, HG[X]PRT, is reported to be essential for the growth of both of these parasites, making it an excellent target for antimalarial drug discovery. Here, we have used rational structure-based methods to design an inhibitor, [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine, of PvHGPRT and PfHGXPRT that has K values of 8 and 7 nM, respectively, for these two enzymes. The crystal structure of PvHGPRT in complex with this compound has been determined to 2.85 Å resolution. The corresponding complex with human HGPRT was also obtained to allow a direct comparison of the binding modes of this compound with the two enzymes. The tetra-(ethyl l-phenylalanine) tetraamide prodrug of this compound was synthesized, and it has an IC of 11.7 ± 3.2 μM against Pf lines grown in culture and a CC in human A549 cell lines of 102 ± 11 μM, thus giving it a ∼10-fold selectivity index.
PubMed: 29161011
DOI: 10.1021/acschembio.7b00916
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.773 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon